Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

… And Heart Drug With Theravance

by Rick Mullin
October 22, 2012 | A version of this story appeared in Volume 90, Issue 43

Merck & Co. and Theravance have formed a partnership to discover, develop, and commercialize small molecules directed at targets being investigated for their involvement in hypertension and heart failure. Merck will make an up-front payment of $5 million, gaining an exclusive license to Theravance’s therapeutic candidates. Theravance is eligible to receive additional milestone payments of up to $148 million for the first indication, as well as royalties.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.